Earnings Feed
Start Free
Eloxx Pharmaceuticals, Inc.·4

May 8, 4:44 PM ET

Walts Alan Edmund 4

Research Summary

AI-generated summary

Updated

Eloxx (ELOX) Director Alan Walts Receives RSUs and Exercises Options

What Happened

  • Alan Edmund Walts, a director of Eloxx Pharmaceuticals (ELOX), was granted 395,680 restricted stock units (RSUs) on Sept 19, 2025 (reported at $0). The Form 4 also shows activity on Jan 24, 2026 in which 1,875 derivative shares were converted/exercised and a matching 1,875 shares were reported as disposed; both the acquisition/disposition entries are reported with $0 (one acquisition line shows price as N/A).
  • The RSU grant is an award (no cash purchase). The Jan 24, 2026 activity reflects conversion/exercise of derivative securities and a same-day disposition of the resulting shares (reported values $0 / N/A in the filing).

Key Details

  • Transaction dates and reported amounts:
    • 2025-09-19: Grant/award (A) — 395,680 RSUs @ $0.00 (derivative award).
    • 2026-01-24: Exercise/conversion (M) — 1,875 shares acquired (price N/A) and 1,875 shares disposed @ $0.00.
  • Shares owned after the transactions: Not specified in the provided data (not reported here).
  • Relevant footnotes from the filing:
    • F1: Each RSU represents a contingent right to receive one share of common stock.
    • F2: The stock option vests 1/36 on Oct 31, 2025, then monthly over 35 months, subject to continuous service.
    • F3: The RSUs vested 50% on the first anniversary of Jan 24, 2024, with the remainder vesting in two equal annual installments.
  • Timeliness: The Form 4 was filed May 8, 2026 for activity dated Sept 19, 2025 and Jan 24, 2026 — this appears to be a late filing relative to the typical 2-business-day Form 4 deadline.

Context

  • RSU grants (award A) are compensation and do not imply an outlay by the insider; they are commonly used for pay/retention. The filing shows both an exercise/conversion and a same-day disposition of 1,875 derivative shares — the filing reports $0/N/A amounts and does not explain the reason for the disposition (e.g., transfer, tax withholding, or other plan mechanics).
  • For retail investors, grants and vesting schedules are useful to track potential future share issuance; same-day exercise/disposal activity can reflect routine plan settlements rather than a directional investment bet.